Lexatumumab Biosimilar - Research Grade

Human

TNFRSF10B

>1mg/ml

IgG1 - lambda2

CHO Cells

Benufutamab Biosimilar - Research Grade (ICH5390), Conatumumab Biosimilar - Research Grade (ICH5445), Drozitumab Biosimilar - Research Grade (ICH5491), Tigatuzumab Biosimilar - Research Grade (ICH5921), Tilogotamab Biosimilar - Research Grade (ICH5922)

https://www.imgt.org/mAb-DB/

ICH3002

O14763

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of lexatumumab, a fully human antibody built around the death receptor DR5 (TRAIL-R2 / TNFRSF10B). Unlike neutralizing biosimilars, the originator is an agonistic antibody that engages and clusters DR5 to trigger receptor-mediated apoptosis, and the analog reproduces this DR5-binding specificity for research use. It is supplied for research use only (RUO) as an unconjugated preparation and is not the clinical drug, not for human or veterinary use. Typical research applications include use as a defined, well-characterized binding and receptor-engagement reagent in apoptosis and cell-death signaling studies, as a benchmark or positive control in DR5-targeting antibody and ligand comparisons, and as a starting molecule for ADC development, ADCC/effector-function assays, and preclinical in-vitro/ex-vivo model work. It is available at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities to support screening, assay standardization, and scale-dependent experiments. Presented as guidance for ichorbio to review. TNFRSF10B encodes death receptor 5 (DR5, also TRAIL-R2, CD262, KILLER, APO-2), a type I transmembrane member of the TNF receptor superfamily and one of the two agonistic receptors for TRAIL (TNFSF10). Its cytoplasmic region contains a death domain that, upon ligand-induced or antibody-induced receptor clustering, recruits the adaptor FADD and pro-caspase-8/10 to assemble the death-inducing signaling complex (DISC). DISC assembly drives caspase-8 activation and extrinsic apoptosis, with amplification through the intrinsic mitochondrial pathway in type II cells. DR5 is broadly expressed and frequently upregulated on tumor cells, and its engagement can also modulate NF-kB and non-apoptotic signaling. Because DR5 activation can selectively induce apoptosis in transformed cells, it is a long-standing target in cancer cell-death research.

Death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL receptor 2, TRAIL-R2, Tumor necrosis factor receptor superfamily member 10B, DR5, KILLER, TRICK2, ZTNFR9

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Lexatumumab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Lexatumumab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Lexatumumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Lexatumumab that binds TNFRSF10B; for research use only.